Current Treatments of Post-traumatic Stress Disorder and Amygdala Ablation as a Potential Cutting-Edge Therapy in Its Refractory Cases.

amygdala ablation cognitive behavioral therapy combat fatigue post traumatic stress disorder prolonged exposure shell shock trauma

Journal

Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737

Informations de publication

Date de publication:
Nov 2022
Historique:
accepted: 27 11 2022
entrez: 30 12 2022
pubmed: 31 12 2022
medline: 31 12 2022
Statut: epublish

Résumé

Post-traumatic stress disorder (PTSD)is a very common psychiatric disorder occurring in an individual of any age, gender, or race who underwent trauma, with women being twice more at risk than men. It is generally seen more in American Indians, United States Latinos, and African American ethnic groups. A patient is diagnosed with PTSD if the symptoms of intrusion, avoidance, changes in cognition and emotions, arousal, and mood reactivity changes persist for more than a month and cause the individual severe difficulty in their everyday cognitive and psychological functioning. The psychological treatment includes numerous therapies including trauma-focused therapies such as cognitive behavioral therapy, cognitive processing therapy, prolonged exposure therapy, eye movement desensitization and reprocessing, and non-trauma-focused therapies such as relaxation techniques, interpersonal therapy, and mindfulness. Various pharmacological measures have also been tried with mixed results such as selective serotonin reuptake inhibitors, benzodiazepines, adrenergic drugs, atypical antipsychotics, and mood stabilizers like lithium and valproate. As numerous studies have proven, PTSD is linked with right-side stimulation of the amygdala. The purpose of this article is to highlight the use of extremely selective laser ablation of the amygdala-hippocampal unit as a successful surgical intervention for medically unresponsive PTSD and as a revolutionary solution and prospective cutting-edge therapy in the near future.

Identifiants

pubmed: 36582576
doi: 10.7759/cureus.31943
pmc: PMC9794924
doi:

Types de publication

Journal Article Review

Langues

eng

Pagination

e31943

Informations de copyright

Copyright © 2022, Prajjwal et al.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Behav Sleep Med. 2020 Nov-Dec;18(6):809-819
pubmed: 31739686
J Consult Clin Psychol. 1992 Oct;60(5):748-56
pubmed: 1401390
Am J Psychiatry. 2005 Feb;162(2):214-27
pubmed: 15677582
J Clin Psychol. 1997 Dec;53(8):847-52
pubmed: 9403387
Neurosurgery. 2020 Sep 15;87(4):796-802
pubmed: 32259241
J Consult Clin Psychol. 2004 Feb;72(1):3-18
pubmed: 14756610
Nat Neurosci. 2008 Feb;11(2):232-7
pubmed: 18157125
N Engl J Med. 2018 Feb 8;378(6):507-517
pubmed: 29414272
Neuroscience. 2003;122(4):1093-105
pubmed: 14643775
J Neurosci. 2008 Oct 22;28(43):10803-13
pubmed: 18945888
J Physiol. 2013 May 15;591(10):2381-91
pubmed: 23420655
Biol Mood Anxiety Disord. 2011 Oct 12;1(1):6
pubmed: 22738183
Psychiatry Res. 2017 Mar;249:86-93
pubmed: 28086181
Trends Neurosci. 2011 Aug;34(8):411-20
pubmed: 21764143
Neuroimage Clin. 2012 Nov 13;2:43-9
pubmed: 24179757
Front Psychiatry. 2018 Oct 22;9:516
pubmed: 30405457
Acta Psychiatr Scand. 2006 Apr;113(4):360-3; discussion 363-4
pubmed: 16638081
Cogn Behav Ther. 2019 Jan;48(1):1-14
pubmed: 30332919
Hum Psychopharmacol. 2004 Oct;19(7):489-94
pubmed: 15378676
J Psychiatr Res. 2013 Oct;47(10):1469-78
pubmed: 23827769
J Affect Disord. 2020 Jan 1;260:410-417
pubmed: 31539674
Trials. 2014 Sep 10;15:356
pubmed: 25208824
Neuroscience. 2006;138(1):197-220
pubmed: 16361065
Cancer Imaging. 2019 Oct 15;19(1):65
pubmed: 31615562
Arch Gen Psychiatry. 2012 Nov;69(11):1169-78
pubmed: 23117638
J Rehabil Res Dev. 2012;49(5):679-87
pubmed: 23015579
J Trauma Stress. 2020 Aug;33(4):465-476
pubmed: 32598569
Evid Based Complement Alternat Med. 2005 Dec;2(4):503-12
pubmed: 16322808
Behav Res Ther. 2005 Apr;43(4):413-31
pubmed: 15701354
Biol Psychol. 2018 Feb;132:228-232
pubmed: 29309826
Quintessence Int. 2004 Mar;35(3):223-7
pubmed: 15119681
Behav Res Ther. 2008 Aug;46(8):913-31
pubmed: 18565493
Brain Sci. 2016 Aug 10;6(3):
pubmed: 27517963
Behav Res Ther. 2000 Apr;38(4):319-45
pubmed: 10761279
J Abnorm Psychol. 2008 May;117(2):479-84
pubmed: 18489226
J Clin Psychiatry. 2014 May;75(5):470-6
pubmed: 24922484
Front Behav Neurosci. 2018 Nov 02;12:258
pubmed: 30450043
Expert Rev Neurother. 2011 Aug;11(8):1151-63
pubmed: 21797656
Annu Rev Neurosci. 2014;37:329-46
pubmed: 25032499
J Clin Psychol. 2002 Aug;58(8):933-46
pubmed: 12115716
Behav Res Ther. 1996 Jul;34(7):533-43
pubmed: 8826760
Front Psychiatry. 2020 Apr 28;11:351
pubmed: 32411032
Annu Rev Neurosci. 2000;23:155-84
pubmed: 10845062
Transl Psychiatry. 2020 Aug 17;10(1):288
pubmed: 32807799
J Clin Psychiatry. 2000;61 Suppl 7:33-9
pubmed: 10795607

Auteurs

Priyadarshi Prajjwal (P)

Neurology, Bharati Vidyapeeth (Deemed to be University) Medical College, Pune, IND.

Pugazhendi Inban (P)

General Medicine, Government Medical College, Omandurar Government Estate, Chennai, IND.

Balaganesh Natarajan (B)

Neurology, St. George's University School of Medicine, True Blue, GRD.

Spandana Mitra (S)

General Medicine, Employee's State Insurance Corporation (ESIC) Medical College & Hospital, Kolkata, IND.

Tamara Tango (T)

Neurology/Neurosurgery/Internal Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, IDN.

Aneeqa Ahmed (A)

General Medicine, Shadan Institute of Medical Sciences, Peeramcheru, IND.

Soniya Bansode (S)

Neurology, Government Medical College, Siddipet, Siddipet, IND.

Abdullah A Almushawah (AA)

Neurology, King Saud University, Riyadh, SAU.

Classifications MeSH